Martine A Rothblatt sold $5.1M of UTHR
Chairperson & CEO at UNITED THERAPEUTICS Corp. 9,500 shares at an average of $541.64, traded Oct 5, 2026, filed Oct 6, 2026.
Score components
- +25RoleCEO
- +25Trade size$5.1M at market
- 0Share of holdings soldSold 2.8% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001106578-26-000157, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 5, 2026 | MOption exercise Common Stockindirect: by Trust10b5-1 | +9,500 | $117.76 | $1.1M | 333,943 | 5 d ago |
| Oct 5, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -501 | $536.26 | $269k | 333,442 | 5 d ago |
| Oct 5, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -905 | $537.43 | $486k | 332,537 | 5 d ago |
| Oct 5, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -655 | $538.62 | $353k | 331,882 | 5 d ago |
| Oct 5, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -931 | $539.50 | $502k | 330,951 | 5 d ago |
| Oct 5, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -1,028 | $540.50 | $556k | 329,923 | 5 d ago |
| Oct 5, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -1,239 | $541.66 | $671k | 328,684 | 5 d ago |
| Oct 5, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -918 | $542.56 | $498k | 327,766 | 5 d ago |
| Oct 5, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -783 | $543.54 | $426k | 326,983 | 5 d ago |
| Oct 5, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -1,260 | $544.59 | $686k | 325,723 | 5 d ago |
| Oct 5, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -920 | $545.69 | $502k | 324,803 | 5 d ago |
| Oct 5, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -360 | $546.63 | $197k | 324,443 | 5 d ago |
| Oct 5, 2026 | MOption exercise Stock Optionderivativeindirect: by Trust10b5-1 | -9,500 | $0.00 | $0 | 299,910 | 5 d ago |
Related signals
Other insiders at UNITED THERAPEUTICS Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.2M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.2M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.5M 9,500 shares | -3% | |
| 18Weak | UNITED THERAPEUTICS Corp | Paul A Mahon EVP & GENERAL COUNSEL | $4.7M 8,300 shares | -16% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $3.9M 7,580 shares | -2% | |
| 38Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $1.1M 1,920 shares | -1% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $4.5M 9,500 shares | -3% | |
| 30Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $4.6M 9,500 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.